相关实验视频

Updated: Jun 4, 2025

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

新型纳米大小的N-Thiazolylpyridylamines针对CDK2:设计,分离合成,构造性研究和多方面的In silico分析

Samir Bondock¹, Nada Alabbad¹, Aisha Hossan¹

¹Chemistry Department, Faculty of Science, King Khalid University, 9004, Abha, Saudi Arabia.

Chemico-biological interactions

|January 3, 2025

概括

新型纳米N-thiazolylpyridylamines被合成并测试为潜在的抗癌剂. 化合物5通过抑制循环林依赖性激酶2 (CDK2) 对多个癌症细胞系表现出显著的细胞毒性.

科学领域:

药用化学医学化学
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

癌症仍然是全球主要的死亡原因,需要开发新的治疗药物.
循环素依赖激酶2 (CDK2) 是细胞循环的关键调节剂,使其成为抗癌药物开发的有希望的目标.
纳米材料为癌症治疗提供了增强的药物输送和疗效.

研究的目的:

为了设计,合成和描述新的纳米N-thiazolylpyridylamines.
评估这些化合物的体外抗癌活性与各种人类癌症细胞系相对应.
通过计算方法研究这些化合物作为循环林依赖激酶2 (CDK2) 抑制剂的潜力.

主要方法:

不同合成的N-thiazolylpyridylamines (2-7和10的化合物) 的不同合成.
光谱技术 (NMR,质谱) 和X射线衍射用于结构和纳米晶体的表征.
对HepG2,MCF-7和HCT-116癌细胞系的细胞毒性测定 (IC50测定).
分子对接和动力学模拟以预测CDK2抑制和结合模式.

主要成果:

合成的纳米N-thiazolylpyridylamines表现出具有纳米尺寸 (10.7557.77 nm) 的晶体结构.
化合物5对MCF-7,HepG2和HCT116细胞系具有强大的细胞毒性,其IC50值处于低微分子范围.
化合物4,6和10对MCF-7细胞系表现出中度活性.
计算分析强烈建议CDK2作为可能的分子目标,并预测了结合相互作用.

结论:

合成的纳米N-thiazolylpyridylamines具有显著的抗癌潜力.
化合物5是作为针对CDK2.2的抗癌剂进一步开发的有希望的主要候选物.
纳米级结构特征可能有助于增强细胞吸收和治疗疗效.

关键词:

这是一种CDK2抑制剂.符合性研究 (conformational studies) 是一种研究.不同合成的综合.分子对接是分子对接.它们是N-Thiazolylpyridylamines的组成部分.纳米大小的化合物纳米大小的化合物

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...